Login to Your Account

Somaxon Slumps as FDA Seeks Further Analyses of Silenor Data

By Jennifer Boggs

Thursday, April 9, 2009
With limited cash and a pipeline narrowed to a single drug - Silenor (doxepin), an H1 histamine blocker for insomnia - San Diego-based Somaxon Pharmaceuticals Inc. is crossing its fingers that a reanalysis of clinical data will provide sufficient answers to the FDA's February complete response and finally get the drug to market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription